Near 15% Weight Loss With Novel Oral GLP-1 RA in Phase II Obesity Trial
SAN DIEGO — Orforglipron, an investigational nonpeptide GLP-1 receptor agonist, helped people with obesity lose a significant amount of weight in a phase II trial. Tested at four once-daily doses — 12, 24, 36, or 45 mg — patients on orforglipron lost between 8.6% to 12.6% of body weight compared with a 2% change seen […]